• 2019 GAPNA Pharmacology Conference: Contemporary Pharmacology and Prescribing in Older AdultsJoin us at the 2019 GAPNA Pharmacology Conference:
    Contemporary Pharmacology and Prescribing in Older Adults

    March 28-30, 2019, Chicago Hilton, Chicago, IL.

    Earn up to 11.5 CNE hours.

     

    Find out more about it and REGISTER today!

  • AwardCall for Excellence Award Nominations

    The awards are: Emerging Chapter Award, Established Chapter Excellence Award, Special Interest Group Excellence Award, Excellence in Clinical Practice Award, Excellence in Community Service Award, Excellence in Education Award, Excellence in Leadership Award, and Excellence in Research Award.

    The nominations are tallied in July and the winners are announced every year during the Awards Celebration at the GAPNA Annual Conference.

    Now is the time to nominate a colleague or yourself - DEADLINE is June 1, 2018.

    Get started... nominate today!

  • W A N T E D   G A P N A   L E A D E R S!
    Call for Nominations!

    Have you ever considered stepping forward, accepting the challenge and volunteering for a position on the 2019 National Board of Directors? Register online NOW by April 1, 2019!

    Step Up - NOW is the Time! Register Here>

  • FREE continuing education credit is available for the following session:

    "Keynote Address - Health Policy: APRNs Working to the Full Extent of the Law"

    (session captured at the GAPNA 2018 Annual Conference)


    For March/April 2019 - Get Your Free CNE Now!

  • Poster Presentation

       

    This 22-module curriculum provides a basic knowledge base for Nurse Practitioners who looking to advance their expertise in caring for patients with dementia.
     

    FREE to GAPNA members until September 1, 2019

  • GAPNA Exchange

       

    GAPNA Exchange is a private, secure community for members to share ideas, ask questions, lend expertise, and network with peers.

    It features both an Open Forum discussion area along with smaller, segmented communities.

    Interact with GAPNA members wherever and whenever!

    Go to GAPNA Exchange

Risk Gene Neutralized

Alzheimer's-Related Risk Gene Neutralized in Human Brain Cells

In a human brain-cell model, a version of the APOE gene – APOE ε4, which increases a person’s risk of developing Alzheimer’s disease – has been successfully made harmless by using an innovative technique.

A study in Nature Medicine shows a possible way to restore normal function to human neurons through the use of gene editing and a small molecule that changed a harmful protein.

The APOE gene comes in several forms, or alleles. Having one copy of the APOE ε4 allele more than doubles a person’s risk for developing late-onset Alzheimer’s and is associated with an earlier age of disease onset. In contrast, the APOE ε3 allele neither increases nor decreases Alzheimer’s risk.

The APOE gene produces the ApoE protein, which can prompt a sequence of biochemical events leading to Alzheimer’s-related damage in the brain.

Researchers from the Gladstone Institute of Neurological Disease and the University of California, San Francisco, derived brain cells from induced pluripotent stem cells – adult cells that have been programmed in a way that allows them to become any type of human cell – using skin cells from people with either APOE ε4 or APOE ε3 genes.

Their observations showed APOE ε4 triggers the development of various Alzheimer’s pathologies in brain neurons, including an increase in APOE fragmentation, tau phosphorylation, production of beta-amyloid (a protein that accumulates into harmful plaques), and degeneration or loss of GABAergic neurons (which affect neurotransmitters).

The researchers determined how to neutralize the abnormalities caused by APOE.

First, they used gene editing to convert the harmful form of the APOE gene to the neutral form, which removed the resulting protein’s detrimental effects. In addition, the researchers used a small-molecule “corrector” they had previously developed to turn the ApoE4 protein into an ApoE3-like protein.

The results were similar: Alzheimer’s pathologies were reduced, and the cells’ normal function was restored.

The authors noted ApoE4 protein results in beta-amyloid production in human but not mouse neurons, and that conversion of ApoE4 to ApoE3 by gene editing significantly lowered beta-amyloid production, consistent with a specific effect of ApoE4.

These results highlight the differences between mouse and human cellular models of Alzheimer’s disease.

The new study offers a human model of Alzheimer’s disease that may be useful for studying mechanisms underlying Alzheimer’s disease and developing a “corrector” drug targeting ApoE4, which could be tested as a therapy for Alzheimer’s.

For more info, see Wang et al. (2018). Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nature Medicine. doi:10.1038/s41591-018-0004-z. [Epub ahead of print]

Plan your trip to the nation’s capital during the GAPNA Annual Conference, September 26-29, 2018 by checking out all the things to do, places to eat, and ways to have fun.

Find out about it!